Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 2/20 | 0.80 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.80 |
| ▸ | STS | P08842 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 5/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.76 |
| ▸ | ESR1 | P03372 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | PGR | P06401 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 2/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6364570 | 1.00 | ABCC4 (0.80) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL6364171 | 0.89 | ABCC4 (0.75) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL4395104 | 0.89 | ABCC4 (0.75) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL232796 | 0.89 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL29392632 | 0.89 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL30471686 | 0.89 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL232797 | 0.89 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| E2Mate SCHEMBL10070158 | 0.88 | STS (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| E2Mate SCHEMBL5151234 | 0.88 | STS (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL20634998 | 0.88 | ABCC4 (0.83) | ABCC4ABCC1STSKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889727-B1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2006-03-08 | — | — | EP | claimed |
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | STERIX LIMITED (GB) | 2002-05-23 | — | — | US | claimed |
| EP-0889727-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-13 | — | — | EP | claimed |
| WO-1997033589-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-18 | — | — | WO | claimed |
| US-20120225853-A1 | HORMONE REPLACEMENT THERAPY AND DEPRESSION | Bayer Pharma AG (DE) | 2012-09-06 | — | — | US | disclosed |
| US-7629334-B1 | treating hormone deficiency and hormone irregularity symptoms; free of estrogen, no cancer side effect; [4-[17 beta Methoxy-17 alpha -(methoxymethyl)-3-oxoestra-4,9-dien-11 beta -yl]benzaldehyd-(1E)-oxim] | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-12-08 | — | — | US | disclosed |
| EP-1635843-B1 | THERAPY COMPRISING DIENOGEST FOR HORMONE REPLACEMENT AND DEPRESSION | BAYER SCHERING PHARMA AG (DE) | 2009-01-07 | — | — | EP | disclosed |
| EP-1605924-B1 | MESOPROGESTINS (PROGESTERONE RECEPTOR MODULATORS) AS A COMPONENT OF COMPOSITIONS FOR HORMONE REPLACEMENT THERAPY (HRT) | BAYER SCHERING PHARMA AG (DE) | 2008-11-05 | — | — | EP | disclosed |
| EP-0889727-B1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1423407-B1 | 4-HALOGENATED 17-METHYLENE STEROIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | SCHERING AG (DE) | 2006-03-08 | — | — | EP | disclosed |
| US-6855836-B2 | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds | JENAPHARM GMBH & CO. KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20050032758-A1 | Hormone replacement therapy and depression | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-10 | — | — | US | disclosed |
| US-20020091112-A1 | 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-07-11 | — | — | US | disclosed |
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | STERIX LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2002019971-A1 | 4-HALOGENATED 17-METHYLENE STEROIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | JENAPHARM GMBH & CO. KG (DE) | 2002-03-14 | — | — | WO | disclosed |
| EP-1150662-A1 | LAMINATES CONTAINING AN ACTIVE SUBSTANCE FOR TRANSDERMAL SYSTEMS | Jenapharm GmbH & Co. KG (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000047191-A1 | LAMINATES CONTAINING AN ACTIVE SUBSTANCE FOR TRANSDERMAL SYSTEMS | JENAPHARM GMBH & CO. KG (DE) | 2000-08-17 | — | — | WO | disclosed |
| US-6080735-A | SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES | JENAPHARM GMBH & CO. KG (DE) | 2000-06-27 | — | — | US | disclosed |
| EP-0889727-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997033589-A1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | ESRRA, ESR2, CYP19A1 | ABCC4 2078/4885ABCC1 819/4885STS 124/4885 |
| US-20020091112-A1 | 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds | CYP17A1, HSD17B11, CYP19A1 | ABCC4 2437/4885ABCC1 4153/4885STS 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.